https://orcid.org/0000-0003-3817-6696
References
- Noguera-Morel L, Gerlero P, Torrelo A, Hernández-Martín Á. Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: a series of 15 cases. J Am Acad Dermatol. 2017;76(3):567–570. doi:10.1016/j.jaad.2016.10.034
- Searle T, Ali FR, Al-Niaimi F. Perioral dermatitis: diagnosis, proposed etiologies, and management. J Cosmet Dermatol. 2021;20(12):3839–3848. doi:10.1111/jocd.14060
- Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN Phase 3 trial. J Am Acad Dermatol. 2022;86(1):104–112. doi:10.1016/j.jaad.2021.05.075
- Bennett M, Moussa A, Sinclair R. Successful treatment of chronic severe alopecia areata with abrocitinib. Australas J Dermatol. 2022;63(2):274–276. doi:10.1111/ajd.13836
- Zhang L, Guo L, Wang L, Jiang X. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis. J Eur Acad Dermatol Venereol. 2022;36(11):1937–1946. doi:10.1111/jdv.18263
- Bao C, Xu Q, Xiao Z, et al. Abrocitinib as a novel treatment for lichen sclerosus. Br J Dermatol. 2023;189(1):136–138. doi:10.1093/bjd/ljad129
- Li Y, Jiang Y, Sun J. Improvement of Hailey-Hailey disease with abrocitinib. Clin Exp Dermatol. 2023;48(5):532–533. doi:10.1093/ced/llad023
- Arnet L, Erfurt-Berge C. Effect of abrocitinib in a patient with extensive necrobiosis lipoidica. J Eur Acad Dermatol Venereol. 2023;37(10). doi:10.1111/jdv.19189
- Vander Does A, Yosipovitch G. Failure of dupilimab with severe prurigo nodularis that responded well to abrocitinib. Dermatitis. 2023. doi:10.1089/derm.2022.0065
- Bai J, Su W, Fang H, Qiao J. Treatment of primary cutaneous lichenoid amyloidosis with abrocitinib: a pilot study in two cases. Int J Dermatol. 2023;62(9). doi:10.1111/ijd.16698